Testing effectiveness (Phase 2)Ended earlyNCT02877082
What this trial is testing
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Who this might be right for
Acute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+9 more
Emory University 5